Efficacy of reduction therapy of natural human β-interferon and ribavirin in elderly patients with chronic hepatitis C, genotype 2 and high virus load.

scientific article published on 26 March 2012

Efficacy of reduction therapy of natural human β-interferon and ribavirin in elderly patients with chronic hepatitis C, genotype 2 and high virus load. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1111/J.1872-034X.2012.00982.X
P8608Fatcat IDrelease_q7dg2maxvjhlrlio5v2ddoi3fi
P698PubMed publication ID22776551

P50authorYusuke KawamuraQ90407021
Hitomi SezakiQ92198438
Kenji IkedaQ114433562
Hiromitsu KumadaQ114433568
Fumitaka SuzukiQ114923480
Masahiro KobayashiQ114923755
Yoshiyuki SuzukiQ114923935
Yasuji AraseQ114924322
Satoshi SaitoQ114924602
Mariko KobayashiQ114924823
Tetsuya HosakaQ56223851
Norio AkutaQ87747459
P2093author name stringNaoki Matsumoto
Yuya Seko
Norihiro Imai
P2860cites workFunctional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritisQ28183279
Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis CQ29619541
Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C.Q41604120
Interferon-beta plus ribavirin for patients with hepatitis C virus genotype 1: a randomised pilot trialQ42844274
Analysis of genotypes and amino acid residues 2209 to 2248 of the NS5A region of hepatitis C virus in relation to the response to interferon-beta therapyQ42981569
Natural human interferon beta plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus and a high viral loadQ42982755
Interferon monotherapy for patients with chronic hepatitis C and normal serum aminotransferase levels at commencement of treatment.Q42987233
Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot studyQ42989003
Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3.Q42993387
Efficacy and safety of combination therapy of natural human interferon beta and ribavirin in chronic hepatitis C patients with genotype 2 and high virus loadQ42997474
Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin.Q42998703
Efficacy and safety of combination therapy of natural human interferon beta and ribavirin in chronic hepatitis C patients.Q43040948
A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C.Q44527614
Suitable treatment period in patients with virological response during combination therapy of peginterferon and ribavirin for chronic hepatitis C.Q50568065
Side effects of combination therapy of peginterferon and ribavirin for chronic hepatitis-C.Q50569792
Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C.Q50577281
A high-throughput SNP typing system for genome-wide association studiesQ57269468
P433issue8
P921main subjectribavirinQ421862
chronic hepatitis CQ55779873
P304page(s)750-756
P577publication date2012-03-26
P1433published inHepatology ResearchQ15752035
P1476titleEfficacy of reduction therapy of natural human β-interferon and ribavirin in elderly patients with chronic hepatitis C, genotype 2 and high virus load
P478volume42

Reverse relations

cites work (P2860)
Q41750179Efficacy and safety of interferon treatment in elderly patients with chronic hepatitis C in Japan: A retrospective study using the Japanese Interferon Database.
Q47888797Efficacy and safety of telaprevir with natural human interferon-β and ribavirin in Japanese chronic hepatitis C patients with depression
Q42090330Evolution of viral RNA in a Chinese patient to interferon/ribavirin therapy for hepatitis C.
Q35668734Natural interferon-beta treatment for patients with chronic hepatitis C in Japan

Search more.